160 related articles for article (PubMed ID: 12001999)
1. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
McMichael A; Hanke T
Nat Rev Immunol; 2002 Apr; 2(4):283-91. PubMed ID: 12001999
[TBL] [Abstract][Full Text] [Related]
2. HIV vaccines 1983-2003.
McMichael AJ; Hanke T
Nat Med; 2003 Jul; 9(7):874-80. PubMed ID: 12835708
[TBL] [Abstract][Full Text] [Related]
3. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
Masopust D
J Intern Med; 2009 Jan; 265(1):125-37. PubMed ID: 19093965
[TBL] [Abstract][Full Text] [Related]
4. [Development of an AIDS vaccine: status report].
Girard MP
Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
[TBL] [Abstract][Full Text] [Related]
5. New hope for an AIDS vaccine.
Robinson HL
Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.
Fernandez CS; Smith MZ; Batten CJ; De Rose R; Reece JC; Rollman E; Venturi V; Davenport MP; Kent SJ
J Virol; 2007 Apr; 81(8):4137-44. PubMed ID: 17251297
[TBL] [Abstract][Full Text] [Related]
7. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines against human immunodeficiency virus type 1.
Estcourt MJ; McMichael AJ; Hanke T
Immunol Rev; 2004 Jun; 199():144-55. PubMed ID: 15233732
[TBL] [Abstract][Full Text] [Related]
10. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
11. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
12. T lymphocyte responses in HIV-1 infection: implications for vaccine development.
Brander C; Walker BD
Curr Opin Immunol; 1999 Aug; 11(4):451-9. PubMed ID: 10448136
[TBL] [Abstract][Full Text] [Related]
13. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
14. [HIV/AIDS vaccines: heading for new vaccine approaches?].
Girard MP
Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
[TBL] [Abstract][Full Text] [Related]
15. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.
Russell ND; Hudgens MG; Ha R; Havenar-Daughton C; McElrath MJ
J Infect Dis; 2003 Jan; 187(2):226-42. PubMed ID: 12552447
[TBL] [Abstract][Full Text] [Related]
16. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
Calarota SA; Weiner DB; Lori F; Lisziewicz J
Vaccine; 2007 Apr; 25(16):3070-4. PubMed ID: 17292518
[TBL] [Abstract][Full Text] [Related]
17. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
[TBL] [Abstract][Full Text] [Related]
18. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.
Wille-Reece U; Flynn BJ; Loré K; Koup RA; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15190-4. PubMed ID: 16219698
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
20. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
